Trials / Terminated
TerminatedNCT00744341
Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure
A Double-Blind, Placebo-Controlled, Randomized, Multi-Center, Dose-Finding Study of SLV320, a Selective A1 Adenosine Receptor Antagonist, to Evaluate the Effect on Renal Function and Safety in Subjects Hospitalized With Acute Decompensated Heart Failure and Renal Dysfunction (Reno-Defend 1)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy and safety of IV SLV320 in acute heart failure patients with renal dysfunction.
Detailed description
The purpose of this study is to determine the efficacy and safety of IV SLV320 in acute heart failure patients with renal dysfunction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SLV320 | 1.25mg i.v. bid |
| DRUG | SLV320 | 3.75mg i.v. bid |
| DRUG | SLV320 | 7.5mg i.v. bid |
| DRUG | SLV320 | 15.0mg i.v. bid |
| DRUG | Placebo |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2008-08-29
- Last updated
- 2010-09-17
Locations
105 sites across 11 countries: United States, Canada, Chile, Denmark, France, Germany, Italy, Poland, Romania, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00744341. Inclusion in this directory is not an endorsement.